The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of lisocabtagene maraleucel for treating large B-cell lymphoma after at least 2 therapies.
Please note that following on from advice received from the company further information regarding the timelines of this appraisal will be available in due course.